Fennec Pharmaceuticals (FENC)
Commercializes PEDMARK for pediatric cisplatin-related hearing-loss protection.
$12.33
At close+0.29 (+2.45%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 10 | 25 | 7 | 7 | 8 | 9 | 10 | 12 | 14 | 15 | 18 |
| Cost of revenue | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 |
| Gross profit | 6 | 9 | 25 | 7 | 6 | 7 | 8 | 9 | 12 | 12 | 15 | 17 |
| 7 | 11 | 11 | 12 | 11 | 8 | 9 | 11 | 12 | 15 | 15 | 15 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 11 | 11 | 12 | 11 | 8 | 9 | 11 | 12 | 15 | 15 | 15 | |
| Selling & marketing | 3 | 4 | 5 | 5 | 5 | 4 | 3 | 4 | 5 | 6 | 11 | 11 |
| General & administrative | 4 | 7 | 6 | 7 | 6 | 4 | 6 | 7 | 7 | 8 | 3 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −2 | 14 | −5 | −5 | −1 | −1 | −3 | 0 | −3 | 0 | 2 |
| −1 | −1 | −1 | −1 | −1 | −1 | 0 | 0 | 0 | −2 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −1 | −1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Income before tax | −2 | −3 | 13 | −6 | −6 | −2 | −1 | −3 | −1 | −5 | 0 | 2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −2 | −3 | 13 | −6 | −6 | −2 | −1 | −3 | −1 | −5 | 0 | 2 |
| Net income | −2 | −3 | 13 | −6 | −6 | −2 | −1 | −3 | −1 | −5 | 0 | 2 |
| EPS, basic | −$0.07 | −$0.10 | $0.47 | −$0.20 | −$0.21 | −$0.07 | −$0.04 | −$0.12 | −$0.02 | −$0.17 | $0.01 | $0.06 |
| EPS, diluted | −$0.07 | −$0.10 | $0.41 | −$0.20 | −$0.21 | −$0.06 | −$0.04 | −$0.12 | −$0.02 | −$0.17 | $0.01 | $0.05 |
| Weighted average shares, basic | 26 | 27 | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 31 | 34 | 35 |
| Weighted average shares, diluted | 26 | 27 | 31 | 27 | 27 | 27 | 28 | 28 | 28 | 31 | 36 | 36 |
| EBITDA | −1 | −2 | 15 | −4 | −5 | −1 | −1 | −3 | 0 | −4 | 0 | 2 |
| Depreciation & amortization | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −2 | 14 | −5 | −5 | −1 | −1 | −3 | 0 | −4 | 0 | 2 |